Table 4.
Features | Median OS (month) | Univariate P value | Multivariate P value | HR 95% CI |
---|---|---|---|---|
Age, yr | .80 | |||
≤60 | 15.1 | |||
>60 | 16.1 | |||
Gender | .73 | |||
Female | 18.1 | |||
Male | 15.2 | |||
Smoking status | .27 | |||
Never smoked | NA | |||
Ex-smoker | 16.1 | |||
Current smoker | 15.2 | |||
Stage at diagnosis | .01 | .08 | 4.18 (0.84–19.7) | |
Limited-stage | 23.0 | |||
Extensive-stage | 15.1 | |||
ECOG PS | .34 | |||
0 | 15.1 | |||
1 | 17.0 | |||
2 | NA | |||
Brain metastasis at diagnosis | .22 | |||
Present | 15.2 | |||
Absent | 16.6 | |||
PCI | .06 | |||
Absent | 11.3 | |||
Present | 16.6 | |||
No. of metastatic site | .83 | |||
1 | 16.1 | |||
2 | 16.9 | |||
3 | 15.1 | |||
4 | 15.2 | |||
Liver metastasis | .61 | |||
Present | 15.2 | |||
Absent | 16.6 | |||
NLR | .006 | .34 | 0.57 (0.18–1.82) | |
≤3.43 | 16.9 | |||
>3.43 | 11.3 | |||
PLR | .007 | .58 | 0.71 (0.21–2.34) | |
≤135.7 | 16.9 | |||
>135.7 | 11.5 |
Statistically significant values are marked with bold.
CI = confidence interval, ECOG PS = Eastern Cooperative Oncology Group performance status, HR = hazard ratio, NA = not applicable, NLR = neutrophil-lymphocyte ratio, NR = not reached, PCI = prophylactic cranial irradiation, PLR = platelet-lymphocyte ratio